GlassScriptPhysician profile
David A Pesola
NPI 1285662015
$5,640.40
in general payments reported to CMS, 2019-2025
19 companies · $112 in 2025
The $112 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,942 · 2020: $290 · 2021: $236 · 2022: $151 · 2023: $2,590 · 2024: $320 · 2025: $112.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,969 · Food and Beverage: $1,031 · Gift: $21.66.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,968.67 |
| Food and Beverage | $1,030.74 |
| Gift | $21.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $2,289.16 | 2021-2024 | Corevalve Evolut R, Micra |
| Medtronic Vascular, INC. | $1,708.33 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $329.80 | 2019-2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $220.15 | 2019-2025 | Lifevest |
| Abbott Laboratories | $191.96 | 2021-2023 | Diamondback Coronary |
| E.R. Squibb & Sons, L.L.C. | $153.15 | 2019-2024 | Camzyos |
| Boston Scientific Corporation | $130.11 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $117.55 | 2019-2023 | Farxiga |
| Janssen Pharmaceuticals, INC | $93.99 | 2019-2021 | |
| Amgen INC. | $70.74 | 2019-2024 | Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $58.36 | 2019-2024 | Jardiance |
| Pfizer INC. | $56.89 | 2020-2024 | |
| Edwards Lifesciences Corporation | $52.69 | 2023-2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Abiomed | $49.89 | 2024 | Impella |
| Heartflow, INC. | $44.72 | 2025 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biosense Webster, INC. | $29.51 | 2025 | Na |
| Amarin Pharma, INC. | $14.85 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $14.74 | 2024 | Evkeeza |
| Cardiovascular Systems INC. | $13.81 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Pesola listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.